Heretofore, we commonly assumed that clinical manifestations and adverse sequelae of DIO/MetS/T2DM arose solely/largely from impaired insulin action, and, indeed, IR downregulation is commonly present in many/most cell types in DIO/MetS/T2DM. This evidence concerns the gene INS and metabolic syndrome.